Sign in
Active, not recruitingPhase 3

A Study About the Long-Term Safety of TAK-881 in People With Primary Immunodeficiency Diseases

Key facts

Who runs it
Takeda
Where
Chicago, Dallas, Denver, Durham, Great Neck, Irvine, Macon, New Orleans, Normal, St. Petersburg, The Bronx, Tulsa, and Walnut Creek, United StatesSee the 13 sitesAlso in 8 other countries, 19 sites
Status
Active, not recruiting
Phase
Phase 3
People taking part
53 people enrolled
Started
4 Nov 2024
Expected to end
16 May 2028
Type of study
Interventional
Treatments tested
  • TAK-881
  • Koru 24 G HIgH Flo Subcutaneous Safety Needle Set (investigational in the US)
Record updated
8 April 2026

Who can take part

Age
2 years and older
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 11 criteriaShow less

Who can take part

  • Participants who meet ALL of the following criteria are eligible for this study:
  • Participant must have completed Study TAK-881-3001 (NCT05755035)
  • Participant or, in the case of minors, legally designated representative(s) is/are willing and able to comply with the requirements of the protocol
  • Participant or, in the case of minors, legally designated representative(s) has/have provided informed consent/assent (if applicable), including providing consent for use of the investigational medical device (in US sites only), prior to the initiation of any study procedures

Who cannot take part

  • Participant was enrolled in another clinical study involving an investigational product (IP) or investigational device within 30 days prior to screening (with the exception of Study TAK-881-3001 [NCT05755035])
  • Participant is scheduled to participate in another clinical study involving an IP or investigational device during the course of this study
  • Participant has a serious medical condition such that the participant's safety or medical care would be impacted by participation in this long-term follow-up study
  • New medical condition that developed during participation in Study TAK-881-3001 (NCT05755035), that, in the judgment of the investigator, could increase risk to the participant or interfere with the evaluation of TAK-881 and/or conduct of the study
  • Participant is a family member or employee of the investigator or the investigator's site staff
  • Participants with potential to become pregnant who meet any one of the following criteria:-; Participant has a positive pregnancy test; Participant does not agree to employ a highly effective form of contraception for the duration of the study
  • If participant is pregnant or lactating at the time of screening or intends to become pregnant or begin lactating during the study

Where in United States

Also in 8 other countries, 19 sites

  • Rush University Medical Center-Allergy/ Immunology CenterChicago, United States
  • Allergy Partners of North TexasDallas, United States
  • National Jewish Medical and Research CenterDenver, United States
  • Duke Asthma Allergy and Airway CenterDurham, United States
  • North Shore-Long Island Jewish Health SystemsGreat Neck, United States
  • University of California, Irvine Medical Sciences IIrvine, United States
  • Central Georgia Infectious Disease ConsultantsMacon, United States
  • Louisiana State University Health Science CenterNew Orleans, United States
  • Sneeze, Wheeze, & Itch Associates LLCNormal, United States
  • University of South FloridaSt. Petersburg, United States
  • Montefiore Medical CenterThe Bronx, United States
  • Allergy, Asthma and Immunology CenterTulsa, United States
  • Allergy & Asthma Clinical ResearchWalnut Creek, United States

About the trial

What the trial wants to find out

The main aim of this study is to learn if TAK-881 is safe and well tolerated during long-term use in adults and children with PIDD who are eligible and completed study TAK-881-3001 (NCT05755035).

Read full original descriptionShow less

The participants will receive the first dose of TAK-881 immunoglobulin (IgG) infusion at the same dosage as the last dose administered in study TAK-881-3001 (NCT05755035). After the first TAK-881 infusion in study TAK-881-3002, the dosing interval (can be adjusted by participant/caregiver) and/or the dose of TAK-881 can be adjusted by the study doctor to every 2, 3 or 4 weeks at scheduled site visits.

Participants will visit the clinic every 12 weeks until the End of Study (EOS) visit.

The group in the trial

  • TAK-881Treatment being tested

    Epoch 1: Participants who completed study TAK-881-3001 (NCT05755035) and met eligibility criteria will receive TAK-881 using Koru 24 G HlgH Flo subcutaneous (SC) safety needle set (investigational in the US) at the same dose and same treatment interval as at the last infusion in TAK-881-3001 (NCT05755035) at Week 1 and at Weeks 13 and Week 25 of study TAK-881-3002. Epoch 2: Participants with anti-rHuPH20 antibody titer \>=1:160 at any time point during Study TAK-881-3001 (NCT05755035) and/or Study TAK-881-3002 Epoch 1, will continue receiving TAK-881 every 12 weeks for up to Week 121. After the first TAK-881 infusion in study TAK-881-3002, the interval and/or the dose may be adjusted only at scheduled site visits at the investigator's discretion.

    Treatment: TAK-881 and Koru 24 G HIgH Flo Subcutaneous Safety Needle Set (investigational in the US)

Data and sources

Registry record
Listed on ClinicalTrials.gov and on the EU's official list of trials (CTIS).How to verify a trial in the registry
Official title
Long-term Safety and Tolerability of TAK-881 in Subjects With Primary Immunodeficiency Diseases (PIDD)
Record updated
8 April 2026